Ignite Creation Date:
2025-12-25 @ 3:33 AM
Ignite Modification Date:
2026-01-03 @ 11:07 PM
Study NCT ID:
NCT03052205
Status:
COMPLETED
Last Update Posted:
2020-02-11
First Post:
2017-02-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Sponsor:
Idera Pharmaceuticals, Inc.
Organization:
Study Overview
Official Title:
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ILLUMINATE-101
Brief Summary:
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: